|
Get Full Access To This Report | or | Upgrade to PrivCo Premium |
| $99 Single Company Access | Instant Full Site-Wide Access Currently 50% Off Until May. 31! |
Immucor, Inc.
Business Summary
Founded in 1982, Immucor, Inc., develops, manufactures and sells a complete line of reagents and automated systems that detect and identify certain properties of the cell and serum components of human blood for the purpose of blood transfusion. Immucor Inc.’s offerings are targeted at hospitals, donor centers and reference laboratories. Immucor Inc.’s headquarters are located in Norcross, GA.
Overview & Corporate Organization
Basic Information
| Company Tags: | PE Backed |
| Year Founded: | 1982 |
| Fiscal Year End: | 05/31 |
| 1YR Revenue Growth Rate: | View % |
| 3YR Revenue Growth Rate (CAGR): | View % |
| 1YR Employee Growth Rate: | View % |
| 3YR Employee Growth Rate (CAGR): | View % |
| City: | Norcross |
| State/Province: | Georgia |
| Country: | United States |
| Phone: | View |
| Fax: | View |
| Website: | www.immucor.com |
Corporate Organization
| Parent Companies: | IVD Holdings Inc. |
| Subsidiaries: | |
| Brands: | BeadChip Capture ECHO IMMUTECH NEO |
Industry Information
PrivCo Industries (Sector > Industry > Sub-Industry)
| Healthcare > Medical Devices & Equipment > Medical Diagnostic Equipment |
The PrivCo Industry Classification System™ (PICS) is our proprietary, modernized industry classification system, geared especially toward privately-held companies and including newer emerging sub-industries that are not reflected in other outdated industry classification systems, such as SIC and NAICS.
Competitors & Comparables
Competitors
| Ortho-Clinical Diagnostics |
Charts, Financials, and Statistics (Table Format)
Copy & Paste Financials Into Spreadsheet or
| Income Statement | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
| Net Sales Revenue | View | View | View | View | View | View | View | $144,786,000 | $112,558,000 | $98,647,794 | $84,472,180 | $69,438,114 | $76,540,476 | $59,524,539 | $39,790,434 |
| Cost of Goods Sold | $42,939,244 | ||||||||||||||
| Cost of Goods and Services Sold | View | View | View | View | View | View | View | $57,541,000 | $50,488,000 | $37,477,187 | $38,086,270 | $36,407,764 | $27,550,548 | $18,167,840 | |
| Gross Profit | View | View | View | View | View | View | View | $87,245,000 | $62,070,000 | $55,708,550 | $46,994,993 | $31,351,844 | $40,132,712 | $31,973,991 | $21,622,594 |
| Selling and Marketing Expenses | View | View | View | View | View | View | View | $18,228,000 | $16,182,000 | $13,834,671 | $12,453,906 | $13,254,242 | $12,391,837 | $10,612,516 | $7,255,579 |
| General and Administrative Expenses | View | View | View | View | View | View | View | $18,559,000 | $11,569,000 | $10,185,979 | $9,273,176 | $8,907,861 | $10,533,826 | $8,460,525 | $6,710,838 |
| Other Selling, General and Administrative Expenses | $8,044,000 | ||||||||||||||
| Research and Development Expense (Excluding In - Process) | View | View | View | View | View | View | View | $4,463,000 | $3,749,000 | $2,051,055 | $1,996,742 | $1,893,580 | $2,002,597 | $1,293,576 | $970,924 |
| Amortization | View | View | View | View | View | View | View | $699,000 | $369,000 | $368,374 | $1,620,935 | $1,897,582 | $1,879,049 | $1,091,278 | $588,555 |
| Restructuring Charges | View | View | View | $0 | $0 | ||||||||||
| Merger and Acquisitions Costs | $558,973 | $0 | |||||||||||||
| Impairment of Goodwill | $3,062,519 | $0 | $0 | ||||||||||||
| Litigation Expense | View | View | View | ||||||||||||
| Operating Expense - Other | View | View | View | View | View | View | View | $8,499,000 | $6,964,789 | $6,609,461 | $6,459,707 | $5,966,178 | $3,648,456 | $2,363,293 | |
| Total Operating Expenses excluding costs | View | View | View | View | View | View | View | $49,993,000 | $40,368,000 | $33,404,868 | $31,954,220 | $35,475,491 | $32,773,487 | $25,665,324 | $17,889,189 |
| Operating Income/(Loss) | View | View | View | View | View | View | View | $37,252,000 | $21,702,000 | $22,303,682 | $15,040,773 | ($4,123,647) | $7,359,225 | $6,308,667 | $3,733,405 |
| Interest Expense | View | View | View | View | View | View | View | $662,000 | $881,000 | $2,406,370 | $4,453,802 | $3,746,928 | $2,911,029 | $1,416,179 | $615,705 |
| Interest Income | View | View | View | View | View | View | View | $624,000 | $41,000 | $126,838 | $40,700 | $57,530 | $30,801 | $313,219 | $788,870 |
| Non-operating Income/(Expense) - Other | View | View | View | View | View | View | View | $767,000 | ($598,000) | $158,318 | $1,356,143 | $229,383 | $230,658 | $202,093 | ($27,381) |
| Non-operating Income/(Expense) | View | View | View | View | View | View | View | $729,000 | ($1,438,000) | ($2,121,214) | ($3,056,959) | ($3,460,015) | ($2,649,570) | ($900,867) | $145,784 |
| Income/(Loss) from Continuing Operations Before Income Taxes | View | View | View | View | View | View | View | $37,981,000 | $20,264,000 | $20,182,468 | $11,983,814 | ($7,583,662) | $4,709,655 | $5,407,800 | $3,879,189 |
| Provision for Income Taxes | View | View | View | View | View | View | View | $14,071,000 | $7,726,000 | $5,812,711 | $3,188,904 | $465,451 | $1,897,635 | $1,846,776 | $1,810,416 |
| Net Income (Loss) | View | View | View | View | View | View | View | $23,910,000 | $12,538,000 | $14,369,757 | $8,794,910 | ($8,049,113) | $2,812,020 | $3,561,024 | $2,068,773 |
| Balance Sheet | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
| Cash and Cash Equivalents | View | View | View | View | View | View | View | $37,108,000 | $15,697,082 | $11,183,317 | $4,012,560 | $3,124,517 | $3,505,926 | $2,793,592 |
| Short-Term Investments | View | $1,973,000 | $0 | |||||||||||
| Net Accounts Receivable Trade | View | View | View | View | View | View | View | $34,630,000 | $26,533,796 | $25,693,973 | $27,182,566 | $21,167,490 | $21,726,062 | $21,573,846 |
| Other Accounts and Notes Receivable | $140,946 | |||||||||||||
| Net Income Taxes Receivable | $1,102,198 | $1,024,429 | $592,097 | $402,243 | $752,470 | $553,451 | ||||||||
| Net Other Receivables | $1,235,748 | $2,253,206 | $0 | |||||||||||
| Current Amounts Due From Officers/Stockholders | $395,826 | $0 | ||||||||||||
| Net Inventories | View | View | View | View | View | View | View | $21,836,000 | $20,160,858 | $16,921,216 | $15,557,034 | $15,668,637 | $16,813,239 | $16,065,190 |
| Current Deferred Income Taxes | View | View | View | View | View | View | View | $1,568,000 | $1,545,493 | $2,705,281 | $987,491 | $631,797 | $902,409 | $907,530 |
| Prepaid Expenses | View | View | View | View | View | View | View | $3,767,000 | $2,347,906 | $2,100,890 | $1,834,521 | $891,356 | $1,321,363 | $1,587,817 |
| Current Assets | View | View | View | View | View | View | View | $100,882,000 | $68,623,081 | $61,882,312 | $50,166,269 | $42,281,866 | $45,021,469 | $43,622,372 |
| Net Property, Plant and Equipment | View | View | View | View | View | View | View | $23,035,000 | $23,034,984 | $21,051,235 | $17,027,024 | $18,333,952 | $17,475,882 | $15,697,328 |
| Long-Term Investments | $770,000 | $770,000 | $1,000,000 | $1,000,000 | $1,000,000 | $1,000,000 | ||||||||
| Goodwill | View | View | View | View | View | View | View | $28,826,000 | $28,192,198 | $27,982,234 | $26,541,514 | $28,913,981 | $33,861,147 | $33,634,458 |
| Indefinite-Lived - License Agreements | $1,377,946 | $1,370,620 | $2,307,837 | |||||||||||
| Finite-Lived - Customer Lists | $1,225,000 | $1,310,000 | $1,395,000 | |||||||||||
| Intangible Assets - Other | View | $1,912,000 | ||||||||||||
| Intangible Assets (Excluding Goodwill) | View | View | View | View | View | View | ||||||||
| Noncurrent Deferred Tax Assets | View | View | View | View | View | $1,845,000 | $504,908 | $747,089 | $889,906 | $1,525,936 | $1,120,238 | $1,108,279 | ||
| Deferred Financing Costs | View | View | ||||||||||||
| Other Deferred Long Term Asset Charges | $1,036,904 | $1,652,102 | $2,044,850 | |||||||||||
| Noncurrent Other Assets | View | View | View | View | View | View | View | $1,113,000 | $1,029,752 | $1,765,376 | $2,977,130 | $2,104,845 | $2,251,293 | $2,363,243 |
| Assets | View | View | View | View | View | View | View | $157,613,000 | $124,416,827 | $116,886,192 | $101,367,463 | $95,812,682 | $102,774,879 | $99,733,517 |
| Accounts Payable | View | View | View | View | View | View | View | $8,028,000 | $8,116,645 | $7,949,590 | $8,136,198 | $8,421,602 | $9,442,977 | $10,039,489 |
| Accrued Expenses - Other | $3,009,168 | $3,234,413 | $2,968,701 | $3,561,676 | $4,276,554 | $2,719,496 | ||||||||
| Accrued Salaries | $1,574,758 | $1,364,426 | $1,821,452 | $1,530,772 | $1,346,874 | $1,125,216 | ||||||||
| Accrued Expenses | View | View | View | View | View | View | View | $9,800,000 | ||||||
| Current Notes Payable - Related Parties | $349,654 | $0 | $1,637,495 | |||||||||||
| Current Deferred Income Tax Liabilities | $439,271 | $464,469 | $371,404 | $98,308 | $164,243 | $118,280 | ||||||||
| Current Deferred/(Unearned) Revenue | View | View | View | View | View | View | View | $4,044,000 | $1,174,480 | |||||
| Income Taxes Payable | View | View | View | View | View | View | View | $3,448,000 | $205,495 | $88,087 | $3,165,247 | $23,102 | $74,715 | $27,739 |
| Current Line of Credit | $146,765 | $1,930,521 | $1,995,630 | $2,417,121 | $2,952,307 | $1,619,312 | ||||||||
| Current Portion of Long-Term Debt | View | View | $5,043,450 | $5,047,195 | $3,662,304 | $5,494,829 | $4,277,598 | $5,000,062 | ||||||
| Current Capital Lease Obligations | $652,363 | $931,934 | $975,506 | $848,632 | $618,240 | $194,476 | ||||||||
| Current Other Liabilities | View | View | $4,617,000 | |||||||||||
| Current Liabilities | View | View | View | View | View | View | View | $29,937,000 | $20,362,395 | $21,010,635 | $23,096,442 | $22,745,696 | $23,153,508 | $22,481,565 |
| Line of Credit - Long-Term | $146,610 | $141,431 | $3,033,683 | $3,268,740 | $8,006,213 | $8,052,917 | ||||||||
| Other Debt - Long-Term | $2,081,000 | $18,090,006 | $27,294,082 | $34,839,576 | $25,144,272 | $22,694,938 | ||||||||
| Other Long Term Debt | $6,121,751 | |||||||||||||
| Long-Term Debt | View | View | ||||||||||||
| Capital Lease Obligations - Long-Term | $910,000 | $947,577 | $1,252,948 | $1,843,213 | $1,664,165 | $800,117 | ||||||||
| Commitments and Contingencies | View | View | View | View | View | $0 | $0 | |||||||
| Deferred Tax Liability | View | View | View | View | View | View | View | $2,285,000 | $2,763,243 | $2,916,203 | $2,035,387 | $3,119,402 | $3,062,331 | $3,024,550 |
| Deferred/(Unearned) Revenue - Long-Term | View | View | View | View | View | View | View | $3,515,000 | $616,252 | |||||
| Noncurrent Other Liabilities | View | View | View | View | View | View | View | $1,453,000 | $505,900 | $1,032,440 | $702,047 | $152,588 | $825,592 | $2,626,763 |
| Liabilities | View | View | View | View | View | View | View | $40,181,000 | ||||||
| Common Stock - Value (Excluding Additional Paid in Capital) | View | View | View | View | View | View | View | $6,829,000 | $4,526,451 | $2,894,725 | $770,376 | $727,762 | $746,212 | $748,841 |
| Additional Paid in Capital | View | View | View | View | View | View | View | $30,415,000 | $32,798,742 | $28,156,719 | $19,520,658 | $15,439,889 | $16,848,804 | $16,945,885 |
| Retained Earnings | View | View | View | View | View | View | View | $79,857,000 | $55,956,052 | $43,426,295 | $29,056,538 | $20,261,628 | $28,310,741 | $25,498,721 |
| Other Accumulated Comprehensive Income, Net of Tax Effect | View | View | View | View | View | View | View | $331,000 | ($328,146) | ($782,262) | ($5,394,698) | ($6,585,812) | ($4,986,959) | ($3,140,780) |
| Stockholders' Equity | View | View | View | View | View | View | View | $117,432,000 | $92,953,099 | $73,695,477 | $43,952,874 | $29,843,467 | $40,918,798 | $40,052,667 |
| Liabilities and Stockholders' Equity | View | View | View | View | View | View | View | $157,613,000 | $124,416,827 | $116,886,192 | $101,367,463 | $95,812,682 | $102,774,879 | $99,733,517 |
| Cash Flow Statement | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
| Operating Activities Beginning Net Income | View | View | View | View | View | View | View | $23,910,000 | $12,538,000 | $14,369,757 | $8,794,910 | ($8,049,113) | $2,812,020 | $3,561,024 | $2,068,773 |
| Amortization | $818,191 | $2,241,792 | $1,930,920 | $1,889,587 | $1,091,278 | $588,555 | |||||||||
| Depreciation and Amortization | View | View | View | View | View | View | View | $7,442,000 | $6,440,000 | $5,144,326 | $4,494,661 | $4,228,545 | $2,936,615 | $2,215,848 | $1,392,534 |
| Adjustment Accretion | View | View | View | $0 | $0 | ||||||||||
| Total Adjustments to Provision for Doubtful Accounts | View | View | View | View | View | View | View | $942,000 | $206,000 | $641,996 | $819,167 | $673,997 | $452,983 | ||
| Asset Impairment Charges | View | $0 | $0 | $230,000 | $268,539 | $3,062,519 | $0 | $0 | |||||||
| Adjustments to Realized Gains/(Losses) on Sale of Investments | $530,000 | $0 | $0 | ||||||||||||
| Gain/(Loss) on Sale/Retirement of Property, Plant and Equipment | View | View | View | View | View | View | View | ($700,000) | ($189,000) | ($111,200) | |||||
| Tax Benefit from Exercise of Stock Options | View | View | View | View | View | View | View | $0 | |||||||
| Adjustment for Equity Based Compensation Expense | View | View | View | View | View | View | View | $21,000 | |||||||
| Total Adjustment Employee Compensation | $0 | ||||||||||||||
| Adjustment Realized Gains Losses On Sale Asset | View | ||||||||||||||
| Deferred Income Taxes | View | View | View | View | View | View | View | ($1,635,000) | ($601,092) | ($530,583) | ($143,950) | $79,110 | $225,045 | $481,340 | |
| Adjustment Extraordinary Items | ($924,000) | $0 | $0 | ||||||||||||
| Other Adjustments to Common Stockholders' Net Income - Increase/(Decrease) | View | View | View | View | $369,000 | $0 | $0 | $806,108 | $0 | $0 | |||||
| Noncash Expenses - Other | View | View | View | ||||||||||||
| Total Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities | $10,122,000 | $5,924,060 | $4,294,855 | $10,429,261 | $3,255,911 | $2,424,111 | $1,714,538 | ||||||||
| Change Accounts Receivable | View | View | View | View | View | View | View | $8,786,000 | $491,000 | ($4,056,154) | $6,995,826 | $115,425 | $680,156 | $2,382,232 | $1,147,751 |
| Change Other Receivable | $1,785,881 | $0 | $0 | ||||||||||||
| Current Increase/(Decrease) in Amounts Due From Officers/Stockholders | ($395,826) | $395,826 | ($140,946) | ($554,484) | ($913,570) | ||||||||||
| Change Income Taxes Receivable | View | View | View | View | View | ||||||||||
| Increase/(Decrease) in Inventories | View | View | View | View | View | View | View | $2,015,000 | $3,323,000 | $2,132,654 | ($111,603) | ($1,144,602) | $1,228,317 | $2,749,627 | $800,086 |
| Increase/(Decrease) in Other Current Assets | $706,000 | ($1,393,000) | $835,037 | $288,671 | ($673,612) | $307,185 | $767,083 | ($146,934) | |||||||
| Deferred Income Taxes | ($1,199,000) | ||||||||||||||
| Increase/(Decrease) in Other Non-operating Assets | View | View | View | View | View | View | View | $241,000 | $508,000 | ($72,656) | $594,604 | ($146,448) | ($111,950) | ||
| Increase/(Decrease) in Accounts Payable | View | View | View | View | View | View | View | ($143,000) | $161,000 | $143,435 | ($285,404) | ($795,911) | ($675,764) | $2,383,200 | ($66,145) |
| Increase/(Decrease) in Accrued Expenses | View | View | View | View | View | View | View | $4,249,000 | $450,000 | ||||||
| Increase/(Decrease) in Unearned Premiums | View | View | View | View | View | View | View | $5,768,000 | $936,000 | $430,086 | |||||
| Increase/(Decrease) in Other Current Liabilities | ($510,782) | ($302,295) | $334,101 | $1,967,091 | $1,887,806 | $117,154 | |||||||||
| Change Income Taxes Receivable and Payables Net | View | View | $11,195,000 | $2,800,000 | ($78,311) | $3,605,083 | $358,633 | $370,222 | ($34,608) | $88,433 | |||||
| Increase/(Decrease) in Other Non-operating Liabilities | $946,000 | ($254,000) | $219,773 | $549,459 | ($673,004) | ($1,801,171) | |||||||||
| Net Cash Flows Provided By/(Used In) Operating Activities | View | View | View | View | View | View | View | $41,486,000 | $22,660,000 | $20,293,817 | $13,089,765 | $2,380,148 | $6,067,931 | $5,985,135 | $3,783,311 |
| Purchase of Property, Plant and Equipment | View | View | View | View | View | View | View | $6,593,000 | $7,106,000 | $5,234,192 | $3,367,016 | $5,522,107 | $3,418,430 | $3,129,404 | $1,506,005 |
| Purchase of Held-to-Maturity Securities | $0 | ||||||||||||||
| Proceeds from Other Investments | $1,300,000 | $0 | $0 | ||||||||||||
| Acquisition of Businesses, Net of Cash Acquired | View | View | View | View | View | View | View | $0 | $0 | $523,682 | $32,571,040 | $0 | |||
| Net Other Acquisition/(Divestiture) of Business Activities | $0 | ||||||||||||||
| Cash Acquired From Acquisition | $0 | ||||||||||||||
| Net Proceeds from Sale of Short-Term Investments | View | View | |||||||||||||
| Proceeds/(Payments) on Short-Term Investments | ($1,961,000) | ||||||||||||||
| Purchase Intangible Assets | View | View | View | View | View | View | |||||||||
| Proceeds from Life Insurance Policies | $110,000 | $0 | $0 | ||||||||||||
| Increase Decrease Deposits | View | View | View | ||||||||||||
| Total Increase/(Decrease) in Other Non-operating Assets, Net | ($258,972) | ($2,709,599) | ($35,014) | ||||||||||||
| Proceeds from Sale of Property, Plant and Equipment | View | View | View | $28,000 | $0 | $0 | |||||||||
| Net Other Investing Activities | View | $0 | $85,960 | $2,387,449 | $0 | ||||||||||
| Net Cash Flows Provided By/(Used In) Investing Activities | View | View | View | View | View | View | View | ($7,116,000) | ($7,106,000) | ($5,234,192) | ($3,367,016) | ($5,522,107) | ($4,287,044) | ($40,797,492) | ($1,541,019) |
| Proceeds from Lines of Credit | View | View | View | $5,379,103 | |||||||||||
| Repayments on Lines of Credit | View | View | View | $152,000 | ($70,000) | ||||||||||
| Net Change Line Credit | ($3,351,534) | ($496,403) | $2,058,297 | $555,068 | ($86,363) | ||||||||||
| Net Proceeds from Issuance of Long-Term Debt and Capital Securities | View | View | View | $12,000,000 | $0 | $0 | $7,474,196 | $24,131,114 | $0 | ||||||
| Repayments of Other Long-Term Debt | $5,362,814 | $1,737,409 | $1,246,185 | ||||||||||||
| Repayments of Long-Term Debt and Capital Securities | View | View | View | View | View | View | View | $5,805,000 | $26,473,000 | $11,378,290 | $10,978,379 | ||||
| Net Change Long Term Debt | $3,436,817 | ||||||||||||||
| Excess Tax Benefit Stock Option Exercised | View | View | View | View | View | View | View | $0 | |||||||
| Debt Issuance Costs | View | View | View | $153,000 | $1,050,000 | $763,862 | $325,144 | $43,830 | |||||||
| Increase/(Decrease) in Other Long Term Debt | ($349,654) | $349,654 | ($1,633,947) | $0 | |||||||||||
| Proceeds from Stock Options Exercised | View | View | View | View | View | View | View | $1,582,000 | $3,299,000 | $7,865,001 | $2,816,097 | $0 | $2,986,523 | $1,684,472 | $614,397 |
| Repurchase of Common Stock | View | View | View | View | View | View | View | $8,028,000 | $0 | ||||||
| Repurchase of Other Equity | $9,000 | $8,000 | |||||||||||||
| Payment for Repurchases of Equity | $0 | $1,484,713 | $3,463,608 | $7,375,950 | $877,383 | ||||||||||
| Payment of Dividends | $0 | ||||||||||||||
| Contributions from - Affiliates | View | View | View | ||||||||||||
| Cash Provided by/(Used in) Financing Activities - Other | $0 | ||||||||||||||
| Net Cash Flows Provided By/(Used In) Financing Activities | View | View | View | View | View | View | View | ($12,412,000) | ($11,265,000) | ($7,914,823) | ($9,772,201) | $4,034,911 | $511,588 | $22,081,330 | ($1,595,534) |
| Effect of Exchange Rate on Cash and Cash Equivalents | View | View | View | View | View | View | View | ($547,000) | $225,000 | $25,955 | $937,495 | ($1,274,361) | ($1,580,141) | ($291,598) | ($548,775) |
| Increase/(Decrease) in Cash and Cash Equivalents | View | View | View | View | View | View | View | $21,411,000 | $4,514,000 | $7,170,757 | $888,043 | ($381,409) | $712,334 | ($13,022,625) | $97,983 |
| Cash and cash equivalents at the beginning of the year | View | View | View | View | View | View | View | $15,697,000 | $11,183,000 | $4,012,560 | $3,124,517 | $3,505,926 | $2,793,592 | $15,816,217 | $15,718,234 |
| Total Cash and cash equivalents at the end of the year | View | View | View | View | View | View | View | $37,108,000 | $15,697,000 | $11,183,317 | $4,012,560 | $3,124,517 | $3,505,926 | $2,793,592 | $15,816,217 |
| Income Taxes Paid | View | View | View | View | View | View | View | $5,353,000 | $6,950,840 | $663,252 | $381,133 | $1,225,635 | $1,459,500 | $1,143,802 | |
| Cash Interest Expense | View | View | View | View | View | View | View | $834,000 | $2,525,472 | $3,397,409 | $3,981,977 | $2,886,256 | $1,270,147 | $662,185 | |
| Fair Value of Assets Acquired | ($1,019,453) | $25,463,127 | $0 | ||||||||||||
| Stock Issued | $338,019 | ||||||||||||||
| Liabilities Assumed | ($33,785) | ($15,789,319) | $0 | ||||||||||||
| Supplemental Other Cash Payments | $523,682 | $32,571,040 | $0 | ||||||||||||
| Supplemental Other Net | View | View | View | View | View | View | View | $385,000 | $695,357 | $419,811 | $710,129 | $3,221,657 | $23,332,632 | $562,361 |
| Financial Notes: | |
| * | Immucor, Inc. fiscal year end: 05/31 |
Charts, Financials, and Statistics (Graphs)
(Copy and paste into spreadsheet or export all Immucor, Inc. financials to Excel and create your own graphs.)
To view the graphs below, unlock this company report for $99 or Upgrade to a PrivCo Premium Subscription for site-wide access to all PrivCo private company research reports.
Immucor, Inc. Net Sales Revenue ($ MM): |
Immucor, Inc. Cost of Goods and Services Sold ($ MM): |
Immucor, Inc. Gross Profit ($ MM): |
Immucor, Inc. Selling and Marketing Expenses ($ MM): |
Immucor, Inc. General and Administrative Expenses ($ MM): |
Immucor, Inc. Research and Development Expense (Excluding In - Process) ($ MM): |
Immucor, Inc. Amortization ($ MM): |
Immucor, Inc. Restructuring Charges ($ MM): |
Immucor, Inc. Litigation Expense ($ MM): |
Immucor, Inc. Operating Expense - Other ($ MM): |
Immucor, Inc. Total Operating Expenses excluding costs ($ MM): |
Immucor, Inc. Operating Income/(Loss) ($ MM): |
Immucor, Inc. Interest Expense ($ MM): |
Immucor, Inc. Interest Income ($ MM): |
Immucor, Inc. Non-operating Income/(Expense) - Other ($ MM): |
Immucor, Inc. Non-operating Income/(Expense) ($ MM): |
Immucor, Inc. Income/(Loss) from Continuing Operations Before Income Taxes ($ MM): |
Immucor, Inc. Provision for Income Taxes ($ MM): |
Immucor, Inc. Net Income (Loss) ($ MM): |
Immucor, Inc. Cash and Cash Equivalents ($ MM): |
Immucor, Inc. Short-Term Investments ($ MM): |
Immucor, Inc. Net Accounts Receivable Trade ($ MM): |
Immucor, Inc. Net Inventories ($ MM): |
Immucor, Inc. Current Deferred Income Taxes ($ MM): |
Immucor, Inc. Prepaid Expenses ($ MM): |
Immucor, Inc. Current Assets ($ MM): |
Immucor, Inc. Net Property, Plant and Equipment ($ MM): |
Immucor, Inc. Goodwill ($ MM): |
Immucor, Inc. Intangible Assets - Other ($ MM): |
Immucor, Inc. Intangible Assets (Excluding Goodwill) ($ MM): |
Immucor, Inc. Noncurrent Deferred Tax Assets ($ MM): |
Immucor, Inc. Deferred Financing Costs ($ MM): |
Immucor, Inc. Noncurrent Other Assets ($ MM): |
Immucor, Inc. Assets ($ MM): |
Immucor, Inc. Accounts Payable ($ MM): |
Immucor, Inc. Accrued Expenses ($ MM): |
Immucor, Inc. Current Deferred/(Unearned) Revenue ($ MM): |
Immucor, Inc. Income Taxes Payable ($ MM): |
Immucor, Inc. Current Portion of Long-Term Debt ($ MM): |
Immucor, Inc. Current Other Liabilities ($ MM): |
Immucor, Inc. Current Liabilities ($ MM): |
Immucor, Inc. Long-Term Debt ($ MM): |
Immucor, Inc. Deferred Tax Liability ($ MM): |
Immucor, Inc. Deferred/(Unearned) Revenue - Long-Term ($ MM): |
Immucor, Inc. Noncurrent Other Liabilities ($ MM): |
Immucor, Inc. Liabilities ($ MM): |
Immucor, Inc. Common Stock - Value (Excluding Additional Paid in Capital) ($ MM): |
Immucor, Inc. Additional Paid in Capital ($ MM): |
Immucor, Inc. Retained Earnings ($ MM): |
Immucor, Inc. Other Accumulated Comprehensive Income, Net of Tax Effect ($ MM): |
Immucor, Inc. Stockholders' Equity ($ MM): |
Immucor, Inc. Liabilities and Stockholders' Equity ($ MM): |
Immucor, Inc. Operating Activities Beginning Net Income ($ MM): |
Immucor, Inc. Depreciation and Amortization ($ MM): |
Immucor, Inc. Adjustment Accretion ($): |
Immucor, Inc. Total Adjustments to Provision for Doubtful Accounts ($): |
Immucor, Inc. Asset Impairment Charges ($ MM): |
Immucor, Inc. Gain/(Loss) on Sale/Retirement of Property, Plant and Equipment ($ MM): |
Immucor, Inc. Tax Benefit from Exercise of Stock Options ($ MM): |
Immucor, Inc. Adjustment for Equity Based Compensation Expense ($ MM): |
Immucor, Inc. Deferred Income Taxes ($ MM): |
Immucor, Inc. Other Adjustments to Common Stockholders' Net Income - Increase/(Decrease) ($ MM): |
Immucor, Inc. Noncash Expenses - Other ($ MM): |
Immucor, Inc. Change Accounts Receivable ($ MM): |
Immucor, Inc. Change Income Taxes Receivable ($ MM): |
Immucor, Inc. Increase/(Decrease) in Inventories ($ MM): |
Immucor, Inc. Increase/(Decrease) in Other Non-operating Assets ($ MM): |
Immucor, Inc. Increase/(Decrease) in Accounts Payable ($ MM): |
Immucor, Inc. Increase/(Decrease) in Accrued Expenses ($ MM): |
Immucor, Inc. Increase/(Decrease) in Unearned Premiums ($ MM): |
Immucor, Inc. Change Income Taxes Receivable and Payables Net ($ MM): |
Immucor, Inc. Net Cash Flows Provided By/(Used In) Operating Activities ($ MM): |
Immucor, Inc. Purchase of Property, Plant and Equipment ($ MM): |
Immucor, Inc. Acquisition of Businesses, Net of Cash Acquired ($ MM): |
Immucor, Inc. Net Proceeds from Sale of Short-Term Investments ($ MM): |
Immucor, Inc. Purchase Intangible Assets ($): |
Immucor, Inc. Increase Decrease Deposits ($ MM): |
Immucor, Inc. Proceeds from Sale of Property, Plant and Equipment ($ MM): |
Immucor, Inc. Net Other Investing Activities ($ MM): |
Immucor, Inc. Net Cash Flows Provided By/(Used In) Investing Activities ($ MM): |
Immucor, Inc. Proceeds from Lines of Credit ($ MM): |
Immucor, Inc. Repayments on Lines of Credit ($ MM): |
Immucor, Inc. Net Proceeds from Issuance of Long-Term Debt and Capital Securities ($ MM): |
Immucor, Inc. Repayments of Long-Term Debt and Capital Securities ($ MM): |
Immucor, Inc. Excess Tax Benefit Stock Option Exercised ($ MM): |
Immucor, Inc. Debt Issuance Costs ($ MM): |
Immucor, Inc. Proceeds from Stock Options Exercised ($ MM): |
Immucor, Inc. Repurchase of Common Stock ($ MM): |
Immucor, Inc. Contributions from - Affiliates ($ MM): |
Immucor, Inc. Net Cash Flows Provided By/(Used In) Financing Activities ($ MM): |
Immucor, Inc. Effect of Exchange Rate on Cash and Cash Equivalents ($ MM): |
Immucor, Inc. Increase/(Decrease) in Cash and Cash Equivalents ($ MM): |
Immucor, Inc. Cash and cash equivalents at the beginning of the year ($ MM): |
Immucor, Inc. Total Cash and cash equivalents at the end of the year ($ MM): |
Immucor, Inc. Income Taxes Paid ($ MM): |
Immucor, Inc. Cash Interest Expense ($ MM): |
Immucor, Inc. Supplemental Other Net ($ MM): |
Immucor, Inc. Total Employees: |
Mergers & Acquisitions
| Date | Status | Target | Buyer | Deal Type | Price | |
| Details | Aug. 2008 | Completed | View | View | Acquisition | View |
| Details | Jul. 2011 | Completed | View1 | View | Acquisition Leveraged Buyout (LBO) Take Private | View |
| Details | Jan. 2013 | Completed | View2 | View | Acquisition Asset Sale | View |
| 1 | TPG Capital acquired Immucor, Inc....Read More → |
| 2 | Fully committed financing has been...Read More → |
Full-length notes are available with Single Report Access or PrivCo Premium Subscription. |
Missing a deal? Tell us about it! tips@privco.com
Public / Private History (PPH™)
| Date | Deal Type | Action | Resulting Status | Valuation | Amount Raised | Public Ticker | |
| Details | Jul. 2011 | View | View | View1 | View | View | View |
| 1 | TPG Capital acquired Immucor, Inc....Read More → |
Full-length notes are available with Single Report Access or PrivCo Premium Subscription. |
Detailed Business Description: Immucor, Inc.
Immucor Inc. Overview
Founded in 1982, Immucor, Inc., develops, manufactures and sells a complete line of reagents and automated systems that detect and identify certain properties of the cell and serum components of human blood for the purpose of blood transfusion. Immucor, Inc. is an in vitro diagnostics company specializing in the area of pre-transfusion diagnostics. Immucor Inc. is working towards full automation of manual rpcoeses in blood bank laboratories. Immucor Inc. is part of the blood banking industry, which generally seeks to prevent transfusion reactions through the testing of blood and blood components prior to transfusion. Because of the potential reaction of antigens and antibodies, Immucor Inc. provides identities of the antigens and antibodies present in patient blood and donor blood before a transfusion. If a donor’s red cells contain antigens that are recognized by antibodies in the patient’s plasma, the transfused red cells could be destroyed in a… Continue Reading →
Supplemental Resources
|
Get Full Access To This Report | or | Upgrade to PrivCo Premium |
| $99 Single Company Access | Instant Full Site-Wide Access Currently 50% Off Until May. 31! |








